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Abstract
Background: The validation of novel prognostic indicators is of greatest interest for the management of
esophageal adenocarcinoma (Barrett’s cancer), particularly for non-metastasized (stage I-IIA) disease. The prognostic
role of tumor infiltrating T-lymphocytes (TILs) in Barrett’s cancer has not been reported so far. Here we evaluated
the impact of TILs on survival, recurrence, and metastasis in Barrett’s cancer, particularly in stage I-IIA patients.
Methods: The levels of the adaptive immune markers CD3, CD8, and CD45RO were analyzed by
immunohistochemistry and image analysis in tissue microarrays consisting of tumor tissues of 118 patients with primary
resected Barrett’s cancer. The findings were correlated with clinicopathological parameters including patient outcome.
Results: In multivariate analysis, a low density of intratumoral CD45RO+ immune cells was an independent
unfavorable factor for disease-free survival in stages I-IIA patients (P = 0.004, RR = 4.7, 95% CI = 1.6-13.5) as well in
the entire cohort (P = 0.048, RR = 2.0, 95% CI = 1.0-4.0). High CD3+ and CD45RO+ levels were associated with
prolonged disease-free survival and overall survival as well with low recurrence rates of disease (P = 0.005 and P =
0.018, respectively). In addition, low CD3+ levels were correlated with a higher frequency of lymph node metastasis
(P = 0.025).
Conclusions: This study demonstrates that the density of CD45RO+ TILs is an independent prognostic factor in
non-metastasized (stage I-IIA) Barrett’s cancer patients and indicates an important role for the adaptive
immunologic microenvironment. The inclusion of CD45RO+ density may help to improve the management of
stage I-IIA Barrett’s cancer.
Background
Barrett’s cancer (esophageal adenocarcinoma), most fre-
quently arising from intestinal metaplasia, has rapidly
increased in incidence over the last decades, faster than
any other gastrointestinal malignancy [1,2]. Despite
advances in the therapy of locally advanced tumors with
multimodal treatment strategies including neoadjuvant
chemo- or radiochemotherapy [3-5], it still remains one of
the most deadly tumors in solid oncology. Therefore, there
is the need of prognostic factors for improved individua-
lized risk stratifications, and alternative treatment options,
like targeted or immunologic therapeutic approaches.
Growth regulation and progression of cancer are not
only influenced by the biological behavior of the tumor
but also by the host defense mechanisms. Host immunity
consists of a complex network of humoral and cellular
components that interact with tumor cells and tumor
stroma. On the cellular level, inflammatory elements
encompass dendritic cells, macrophages, granulocytes
and lymphocytes. Activated, memory- and cytotoxic
tumor infiltrating T-lymphocytes (TILs) are considered
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against cancer cells, related to the cytotoxic activity and
the production of growth modulating cytokines of TIL
[6,7]. Several studies have demonstrated the presence of
TILs in various solid human cancers, most recently
showing the association of an abundance of CD3+, CD8+
or CD45RO+ lymphocytic tumor infiltration with a survi-
val benefit for patients with gastric [8] and colorectal
[9-11] cancer, as well as for patients with endometrial
[12], cervical [13], ovarian [14,15], urothelial [16] and
hepatocellular [17] carcinoma and melanoma [18].
Furthermore, it was argued that the type, density, and
location of immune cells in colorectal cancer have prog-
nostic values that are superior to and independent of
those of the UICC-TNM classification [10,19]. However,
the effect of TILs in the clinical course of Barrett’s cancer
is largely unknown. The validation of novel prognostic
indicators are therefore of greatest interest for the man-
agement of esophageal adenocarcinoma, particularly for
non-metastasized (stage I-IIA) disease.
The aim of this study was to evaluate the impact of
TILs on survival, recurrence, and metastasis in primary
resected Barrett’s cancer, particularly in non-metasta-
sized (stage I-IIA) patients.
Methods
Patient material
In total, 118 patients with adenocarcinomas of the distal
esophagus [(Barrett’s cancer associated with histopatho-
logically identified Barrett’s esophagus (according to
WHO 2000)] [20] were enrolled into this study. The
patients had undergone primary surgical resection with-
out chemo- or radiotherapy at the Department of Sur-
gery, Klinikum rechts der Isar, Technische Universität
München between 1991 and 2004. For all patients for-
m a l i n - f i x e dp a r a f f i n - e m b e d d e dt i s s u ef r o ms u r g i c a l
resection was available and individual patient data
including outcome were acquired with approval from
the ethics committee of the Technische Universität
München. All tumor tissue specimens were procured
from patients giving written informed consent.
Mean age of the patients was 63.6 years (range, 33-
83). Female/male ratio was 9/109. 47 tumors were UICC
stage I, 18 stage IIA, 16 stage IIB, 28 stage III, and 8
stage IV. Lymph node metastases were absent in 65
cases (pN0M0) and present in 51 cases (pN1M0/1). The
medium follow-up of the patients was 33 months for
overall (range: 0.8 to 164 months) and 31 months for
disease-free survival (range: 1.6 to 164 months).
Tissue microarrays
Using a tissue microarray instrument (Beecher Instru-
ments, Sun Prairie, Wisconsin, USA), three representa-
tive areas of each tumor (1.0 mm diameter) were
removed from paraffin-embedded tissue blocks which
had been prepared at the time of resection. Serial sec-
tions were cut for the purpose of immunohistochemistry
and transferred to adhesive slides using the “paraffin-
tape-transfer-system” according to manufacturer’s
instructions (Instrumedics, Hackensack, NJ, USA).
Immunohistochemistry
Immunohistochemical stainings for CD3, CD8, and
CD45RO were carried out using an automated stainer
(Ventana Discovery, Tuscon, AZ, USA) and DAB Map
kit (Ventana). Monoclonal antibodies against CD3 (total
T-cell marker; NeoMarkers, Fremont, CA, USA) were
used in dilution at 1:100, against CD8 (cytotoxic T-cell
marker; Dako, Hamburg, Germany) in dilution at 1:50
and against CD45RO (memory T-cell marker; Dako,
Hamburg, Germany) in dilution at 1:1200.
Image analysis
Slides were analyzed with the use of an image-analysis
workstation (SAMBA microscopic image processor;
Meylan, France), the hardware and software of which
have been first described by Brugal et al [21]. This sys-
tem is fitted with a standard orthoplan microscope
(Leica, Bensheim, Germany) and a colour TV-camera
(JVC (KY-F30), 3-CCD, Tokyo, Japan). T-cells were ana-
lyzed in at least 10 randomly selected high-power fields
(magnification x400 with the Leica microscope). Formal
scoring (labeling index) for each antibody was then per-
formed in one section for each TMA block. A labeling
index resulted from the percentage of nuclear immuno-
positive area in relation to the total nuclear area of infil-
trative tumor cells within the tissue. For feature
extraction we applied the software running on SAMBA
system [22].
Statistical Analysis
Receiver operating characteristic (ROC) analyses were
done to determine cut-off levels for labeling indices of
TILs (CD3, CD8, CD45RO positive lymphocytes) that
correlate with clinical outcome (overall survival). The
optimization of the cut-off determination was done by
significance. All cases were therefore classified into low-
and high-density groups for each marker, that is CD3+
low, CD8+ low, and CD45RO+ low (low-density groups)
and CD3+ high, CD8+ high, and CD45RO+ high (high-
density groups). Correlations between parameters were
performed using the Pearson’s correlation for continu-
ous variables, and for discrete variables the Chi square
test or Fisher’s exact test was used. Disease-free survival
and overall survival were calculated from the date of
surgical resection to the date of first recurrence, death,
or last follow-up and the rates were determined accord-
ing to the Kaplan-Meier method. Comparisons of
Rauser et al. BMC Cancer 2010, 10:608
http://www.biomedcentral.com/1471-2407/10/608
Page 2 of 9survival curves were made using the log-rank test and
multivariate analyses were done using the stepwise Cox
regression analysis. Hazard ratios (risk ratios) were cal-
culated univariate and multivariate and listed together
with the confidence intervals. P values < 0.05 were con-
sidered statistically significant in all analyses, whereas P
values of 0.05 to 0.1 were considered as trend. All statis-
tical analyses were done using the SAS (SAS Institute,
Cary, NC, USA) software package.
Results
Tumor infiltrating lymphocytes (TILs)
Immunohistochemical stainings were available for CD3
in 99 cases, for CD8 in 107 cases, and for CD45RO in
110 cases. Labeling indices of CD3+ ranged from 0.3-
18.8 (mean 5.65), of CD8+ from 0.01-6.2 (mean 0.9) and
of CD45RO+ levels from 0-32.1 (mean 2.1). There was a
significant correlation between the TIL levels of CD3+
and CD8+ TILs (P < 0.001; r = 0.54), CD3+ and
CD45RO+ TILs (P < 0.001, r = 0.4) and CD8+ and
CD45RO+ TILs (P < 0.001; r = 0.53). Cut-off levels with
prognostic relevance were 0.9 for CD3+, 0.5 for CD8+
and 2.0 for CD45RO+.
Correlation between clinicopathologic features and TIL
density
The clinical and pathological characteristics of the
patients grouped by TIL density are summarized in
Table 1. The CD3+ low group showed a higher fre-
quency of lymph node metastasis than the correspond-
ing high group (P = 0.025). Moreover, high CD3+ and
high CD45RO+ levels were associated with less recur-
rence of disease (P =0 . 0 0 5a n dP = 0.018, respectively).
A low density of CD3+ showed a trend with higher
stages of UICC classification (P = 0.086). Nevertheless,
by building the two groups of the early stages I-IIA ver-
sus the late stages IIB-IV within the UICC classification,
a high level of CD3+ immune cells were significantly
associated with early stages (P = 0.025). Furthermore,
low levels of CD45RO+ immune cells showed a trend
for an association with a higher frequency of lymph
node metastasis (P = 0.065), and grading (P = 0.091).
A p a r tf r o mt h a tt h e r ew a sn oc o r r e l a t i o no fl e v e l so f
TILs with the pT category, distant metastasis, grading
and UICC classification.
CD3+ and CD45RO+ TILs as predictors of patient survival
In Kaplan-Meier survival analysis, a correlation between
higher infiltration levels and survival was observed for
CD3+ and CD45RO+ lymphocytes, but not for CD8+
lymphocytes (Figure 1). There were significant differ-
ences in disease-free survival between patients with high
CD3+ levels and low CD3+ levels (median 30.6 months
versus 21.4 months) (P = 0.014), as well between
patients with high CD45RO+ densities and low
CD45RO+ densities (median 31.7 months versus 13.2
months, P = 0.005) (Figure 1A-C). Similar results were
observed for overall survival: CD3+ high and CD45RO+
high groups had a more favorable outcome than the
corresponding low groups (median CD3+ high: 33.0
months versus CD3+ low 25.1 months, median CD45RO
+ high: 33.0 months versus 13.6 months) (P =0 . 0 1 0
each) (Figure 1D-F).
Univariate Cox proportional regression hazard models
for disease-free survival showed a relative risk (RR) of
2.39 for patients whose tumors had a low density of
CD45RO+ cells (95% confidence interval [CI] = 1.28-
4.46, P = 0.007) (overall survival: RR = 2.28, 95% CI =
1.19-4.35, P = 0.013). Relative risks for disease-free and
overall survival for patients with low densities of CD3+
were 1.96 (95% CI = 1.13-3.39, P = 0.016) and 2.06 (95%
CI = 1.18-3.61, P = 0.012), respectively.
We also found that the combined influence of high
densities of CD3+CD8+CD45RO+ cells resulted in an
improved disease-free (P = 0.017) and overall survival (P
= 0.015) as compared to low levels of CD3+CD8
+CD45RO+ (Figure 2). In the group of the patients with
high levels of CD3+CD8+CD45RO+ TILs median dis-
ease-free survival time was 29.0 months as compared to
14.6 months for patients with low densities of combined
CD3+CD8+CD45RO+ cells (overall survival: 33.0 versus
17.7 months) (Figure 2). There was also a statistically
significant prolonged survival, when high densities of
CD3+CD45RO+ cells were combined (disease-free survi-
val P = 0.004, overall survival P = 0.007). P-values for
the combination of CD3+CD8+ cells were P = 0.055 for
disease-free survival and P = 0.029 for overall survival.
For the combination of CD8+CD45RO+ cells there was
a trend in prolonged survival (disease-free and overall
survival each P = 0.059).
Remarkably, in multivariate Cox regression analysis a
high infiltration level of CD45RO+ lymphocytes was a
significant independent prognostic factor beside pN-
and M-category as well for disease-free survival (P =
0.048) as for overall survival (P = 0.028) (Table 2).
Expression patterns of CD8+ and CD45RO+ TILs had
no independent prognostic value, nor did the combina-
tion of CD3+CD8+CD45RO+ TILs.
TIL as a predictor of regional lymph node metastasis
Disease-free and overall patient survival correlated with
a high density of CD45RO+ TILs in pN0 patients, but
not in pN1 patients (Figure 3). pN0 patients with a high
density of CD45RO+ cells had a significant more favor-
able outcome than did patients with low CD45RO+
levels (disease-free survival: P = 0.001, overall survival: P
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lymph node metastasis (pN1) did not benefit from a
high CD45RO+ level. There was no statistically signifi-
cant difference between CD45RO+ levels and survival in
pN1 patients (disease-free survival: P =0 . 7 2 1 ,o v e r a l l
survival: P = 0.399) (Figure 3B and 3D).
Multivariate Cox regression analysis within the pN0-
group revealed that low densities of CD45RO+ cells
were independently associated with an unfavorable
disease-free survival (P = 0.004, RR = 4.7, 95% CI = 1.6-
13.5) (Table 2). In pN1 patients, distant metastasis was
an independent prognostic factor (P = 0.002, RR = 3.6,
95% CI = 1.6-8.0).
Furthermore, the CD3+ low group showed a higher
frequency of lymph node metastasis than the corre-
sponding high group (P = 0.025) and for the CD45RO+
low group there was a trend for a higher presence of
lymph node metastases (P = 0.065) (Table 1).
Table 1 Clinical and pathological characteristics of the patients grouped by TIL density
CD3+ TIL
n=9 9
CD8+ TIL
n = 107
CD45RO+ TIL
n = 110
Characteristics low high P-value low high P-value low high P-value
Total number of patients 42 (42.4%) 57 (57.6%) 50 (46.7%) 57 (53.3%) 17 (15.5%) 93 (84.5%)
Gender 0.453 1.0 0.607
male 38 (38.4%) 54 (54.5%) 46 (43.0%) 53 (49.5%) 15 (13.6%) 87 (79.1%)
female 4 (4.0%) 3 (3.0%) 4 (3.7%) 4 (3.7%) 2 (1.8%) 6 (5.5%)
Tumour stage 0.298 0.688 0.353
pT1 15 (15.3%) 26 (26.5%) 20 (18.9%) 25 (23.6%) 6 (5.5%) 42 (38.5%)
pT2 7 (7.1%) 12 (12.2%) 9 (8.5%) 12 (11.3%) 2 (1.8%) 18 (16.5%)
pT3 20 (20.4%) 18 (18.4%) 21 (19.8%) 19 (17.9%) 9 (8.3%) 32 (29.4%)
Lymph node metastasis 0.025 0.440 0.065
pN0 17 (17.3%) 35 (35.7%) 26 (24.5%) 31 (29.2%) 6 (5.5%) 54 (49.5%)
pN1 25 (25.5%) 21 (21.4%) 24 (22.6%) 25 (23.6%) 11 (10.1%) 38 (34.9%)
Distant metastasis 0.212 0.428 0.108
M0 37 (37.8%) 53 (54.1%) 45 (42.5%) 52 (49.1%) 14 (12.8%) 87 (79.8%)
M1 5 (5.1%) 3 (3.1%) 5 (4.7%) 4 (3.8%) 3 (2.8%) 5 (4.6%)
Residual tumour 0.070 0.276 0.125
R0 33 (34.4%) 51 (53.1%) 41 (39.4%) 51 (49.0%) 13 (12.1%) 81 (75.7%)
R1 8 (8.3%) 4 (4.2%) 7 (6.7%) 5 (4.8%) 4 (3.7%) 9 (8.4%)
Grading 0.273 0.696 0.091
G1 0 (0.0%) 2 (2.1%) 2 (1.9%) 1 (1.0%) 0 (0.0%) 5 (4.6%)
G2 17 (17.5%) 27 (27.8%) 20 (19.0%) 26 (24.8%) 4 (3.7%) 42 (38.9%)
G3 25 (25.8%) 26 (26.8%) 27 (25.7%) 29 (27.6%) 13 (12.0%) 44 (40.7%)
UICC classification 0.086 0.776 0.156
I 11 (11.2%) 24 (24.5%) 16 (15.1%) 23 (21.7%) 4 (3.7%) 38 (34.9%)
II 11 (11.2%) 19 (19.4%) 16 (15.1%) 17 (16.0%) 4 (3.7%) 28 (25.7%)
III 15 (15.3%) 10 (10.2%) 14 (13.2%) 12 (11.3%) 6 (5.5%) 21 (19.3%)
IV 5 (5.1%) 3 (3.1%) 4 (3.8%) 4 (3.8%) 3 (2.8%) 5 (4.6%)
Recurrence of disease 0.005 0.209 0.018
No 13 (13.3%) 33 (33.7%) 21 (19.8%) 30 (28.3%) 4 (3.7%) 50 (45.9%)
Yes 29 (29.6%) 23 (23.5%) 28 (26.4%) 27 (25.5%) 13 (11.9%) 42 (38.5%)
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Page 4 of 9Figure 1 Kaplan-Meier plots of disease-free (A-C) and overall (D-F) survival in primary resected Barrett’s cancer patients according to
CD3+ (A and D), CD8+ (B and E), and CD45RO+ (C and F) tumor infiltrating lymphocytes (TILs). In each cohort high and low TIL densities
were plotted according to the corresponding cut-off values. Blue lines indicate patients with tumors containing high TIL densities, red lines
indicate patients whose tumors had low densities of TILs. P values are calculated by log-rank tests. The 5-year disease-free survival (DFS) rate for
patients with high CD3+ levels was 49.2% compared to 23.6% for patients with low levels of CD3+ TILs (overall survival (OS): 54.7% versus 29.7%).
Patients with high densities of CD45RO+ TILs had a 5-year DFS rate of 45.7% in contrast to 14.9% for patients with low densities of CD45RO+
(OS: 47.9% versus 24.4%).
Figure 2 Kaplan-Meier plots of disease-free (A) and overall (B) survival in primary resected Barrett’s cancer patients as a function of
tumor infiltrating lymphocyte (TIL) density. Survival differences were found when high and low densities of CD3+, CD8+, and CD45RO+
were combined. In each cohort high and low TIL densities were plotted according to the corresponding cut-off values. Blue lines indicate
patients with tumors containing high CD3+CD8+CD45RO+ densities, red lines indicate patients whose tumors had low densities of CD3+CD8
+CD45RO+ TILs. P values are calculated by log-rank tests. The 5-year disease-free survival rate for patients with high levels of CD3+CD8+CD45RO
+ TILs was 42.9% compared to 10.0% for patients with low levels of CD3+CD8+CD45RO+ TILs (overall survival: 51.3% versus 11.7%).
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In this study, we analyzed the impact of tumor infiltrat-
ing lymphocytes (TILs) on survival, recurrence, and
metastasis in primary resected esophageal adenocarci-
noma (Barrett’s cancer), particularly in stage I-IIA
patients. The presence of high numbers of CD45RO+
lymphocytes was an independent predictor of increased
survival particularly in non-metastasized (stage I-IIA)
patients as well in the entire cohort. A high CD3+ level
was further associated with prolonged survival and the
absence of regional lymph node metastasis. Moreover,
high infiltration levels of CD45RO+ and CD3+ T-cells
were correlated with a lower rate of recurrence.
Similar observations were made in different cancer
types. A study on gastric cancer demonstrated the inde-
pendent prognostic value of the density of CD3+, CD8+,
and CD45RO+ lymphocytes for regional lymph node
metastasis and patient survival [8]. Studies on colorectal
cancer showed that TILs predict survival better than
conventional anatomical staging and that a high density
of CD45RO+ lymphocytes is correlated with the absence
of lymphatic vessel invasion [10,11]. In melanoma
patients it was found that brisk TIL infiltration in tumor
predicts sentinel lymph node metastasis [18] and in
early-stage cervical cancer it was demonstrated that a
high number of intraepithelial CD8+ lymphocytes is
associated with the absence of lymph node metastasis
[13]. Also, in vivo experiments and animal models have
provided data supporting the role of TILs in cancer
immunosurveillance [23,24]. Although the influence of
lymphocytic infiltration has been studied in squamous
cell cancer (SCC) of the esophagus [25-27], so far less
information is available about the role of TILs in adeno-
carcinomas of the esophagus (Barrett’s cancer).
To our knowledge, the current study is the first one to
examine the prognostic influence of intratumoral CD3+
total T-lymphocytes, CD8+ cytotoxic T-lymphocytes,
and CD45RO+ memory T-lymphocytes in a large cohort
of primary resected Barrett’s cancer patients (n = 118).
In a previous study of a smaller series of human esopha-
geal carcinomas (n = 70), which encompassed both
squamous cell carcinomas and adenocarcinomas, the
presence of a dense intratumoral CD8+ lymphocytic
infiltration was associated with good prognosis indepen-
dent from tumor stage and nodal stage [28]. However,
we did not find CD8+ TILs to be a prognostic factor in
Barrett’s cancer. A recent work with a cohort of 106
adenocarcinomas of the esophagus failed to show a
prognostic influence of CD3+ and CD8+ TILs [29],
whereas in our cohort patients benefit from a high CD3
+ lymphocytic infiltration. A possible explanation may
be different methods applied to quantify TILs. In the
study of Schumacher et al the number of CD8+ lym-
phocytes was counted by fluorescence microscopy and
individual cases were classified in groups according to
their location and quantification [28]. Zingg et al used
high power field light microscopy and assessed the
number of lymphocytes in two different locations, at the
periphery and in the center of the tumors [29]. In our
study, we used tissue microarrays with core biopsies
taken randomized from the tumor area and the quantifi-
cation of lymphocytic infiltration was done by image
analysis. This approach has been demonstrated to be
representative and has been used in different types of
cancer [8-10, 12, 30].
Metastatic relapse attributable to the presence of
tumor cells within lymph nodes is the most frequent
cause leading to cancer-related death in patients with
esophageal tumors [31]. In the current study, high levels
of CD45RO+ TILs were significantly associated with
improved survival in Barrett’s cancer, on the one hand
in the whole study cohort as well in the subgroup of
non-metastasized patients. We also showed that high
densities of CD45RO+ cells were an independent pre-
dictor of improved overall and disease-free survival. We
found, that recurrence of disease less often occurred in
the presence of high levels of CD45RO+ TILs. This
observation is in line with the functional mechanism of
memory T-lymphocytes, namely providing a more rapid
and effective secondary immune response to previously
encountered antigens [32]. Our data suggest that
CD45RO+ T-lymphocytes within esophageal adenocarci-
nomas function not only locally but also systemically in
tumor-draining lymph nodes to suppress
micrometastasis.
Our results show that the presence of intratumoral
CD45RO+ T-cells is associated with the lack of tumor
metastases in the lymph nodes of Barrett’sc a n c e r
patients. Because the absence of lymph node metastases
is strongly associated with a better prognosis, patients
with high CD45RO+ lymphocyte levels are likely to dis-
play an improved clinical outcome in Barrett’s cancer.
Table 2 Multivariate analyses
Disease-free survival Overall survival
Variable P-value RR 95% CI P-value RR 95% CI
pN0 patients
CD45RO+ (low) 0.004 4.7 1.6-13.5 n. s.
All patients
pN < 0.0001 4.7 2.5-9.0 < 0.0001 4.6 2.4-8.8
M 0.011 3.1 1.3-7.3 0.023 2.8 1.1-6.6
CD45RO+ (low) 0.048 2.0 1.0-4.0 0.028 1.1 1.0-1.2
Abbreviations: CI, confidence interval; n.s., not significant; RR, relative risk.
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Page 6 of 9CD45RO+ and CD3+ TILs within Barrett’s cancer may
serve as criteria for selection and monitoring of patients
for adjuvant immunotherapeutic strategies and can be a
reliable prognostic marker to predict favorable outcome
in patient subgroups. In our study, we focused on the
T-lymphocytic cellular component, but additional stu-
dies are in need to elucidate the mechanisms and
potency of host immunity. This is in particular concern
for the purpose of the development of potential immu-
nomodulatory or targeted cancer therapies that are
Figure 3 Kaplan-Meier plots of disease-free (A and B) and overall (C and D) survival in primary resected Barrett’s cancer patients
according to CD45RO+ tumor infiltrating lymphocytes (TILs) and lymph node status.( A and C) Survival rates in patients without regional
lymph node metastases. (B and D) Survival rates in patients with presence of regional lymph node metastasis. In each cohort high and low TIL
densities were plotted according to the corresponding cut-off values. Blue lines indicate patients with tumors containing high CD45RO+ levels,
red lines indicate patients whose tumors had low densities of CD45RO+. P values are calculated by log-rank tests. The 5-year disease-free survival
(DFS) rate in the group of the patients without lymph node metastases was 69.4% for high CD45RO+ levels compared to 16.7% for patients with
low levels of CD45RO+ levels (overall survival (OS): 69.9% versus 41.7%). In the group of the patients with lymph node metastases the 5-year DFS
rate was 13.1% for patients with high densities of CD45RO+ in contrast to a rate of 15.6% for patients low densities of CD45RO+ (OS: 18.1%
versus 15.3%).
Rauser et al. BMC Cancer 2010, 10:608
http://www.biomedcentral.com/1471-2407/10/608
Page 7 of 9highly required for the treatment of esophageal adeno-
carcinoma due to its aggressive behavior and the limited
success of conventional therapy regimes. Our findings
may provide a basis for risk adopted tumor treatment
through predicting clinical outcome and definition of
patient subgroups with different prognosis. The inclu-
sion of CD45RO+ TIL density may help to improve the
prognostication of stage I-IIA Barrett’s cancer. More-
over, our results may be highly valuable in the context
of future promising adjuvant immunotherapy and for
potential immunomodulatory targeted therapy
approaches.
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